Shi Y, Yang H, Guo R, Guo Z, Li J Y, Wu Y J, Qiu H R
Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Zhonghua Xue Ye Xue Za Zhi. 2024 Jun 14;45(6):566-570. doi: 10.3760/cma.j.cn121090-20231204-00291.
To analyze the sensitivity of cytoplasmic light-chain immunofluorescence with fluorescence in situ hybridization in bone marrow smears (new FISH) for detecting cytogenetic abnormalities in multiple myeloma (MM) . 42 MM patients admitted to the First Affiliated Hospital of Nanjing Medical University from April 2022 to October 2023 were enrolled. The patients with MM were detected by new FISH and CD138 immunomagnetic bead sorting technology combined with FISH (MACS-FISH) or cytoplasmic immunoglobulin FISH (cIg-FISH) to analyze cytogenetic detection results using combination probes which included 1q21/1p32, p53, IgH, IgH/FGFR3 [t (4;14) ], and IgH/MAF [t (14;16) ]. In 23 patients with MM, the abnormality detection rates of cIg-FISH and new FISH were 95.7% and 100.0%, respectively (>0.05). The detection rates of 1q21+, 1p32-, p53 deletion, and IgH abnormalities by cIg-FISH and new FISH were consistent, which were 52.2%, 8.7%, 17.4%, and 65.2%, respectively. The results of the two methods further performed with t (4;14) and t (14;16) in patients with IgH abnormalities were identical. The positive rate of t (4;14) was 26.7%, whereas t (14;16) was not detected. In 19 patients with MM, the abnormality detection rates of MACS-FISH and new FISH were 73.7% and 63.2%, respectively (>0.05). The positivity rate of 1q21+, 1p32- and IgH abnormalities detected by MACS-FISH were slightly higher than those detected by new FISH; however, the differences were not statistically significant (all values >0.05) . The new FISH method has a higher detection rate of cytogenetic abnormalities in patients with MM and has good consistency with MACS-FISH and cIg-FISH.
分析骨髓涂片细胞质轻链免疫荧光联合荧光原位杂交技术（新型荧光原位杂交技术）检测多发性骨髓瘤（MM）细胞遗传学异常的敏感性。纳入2022年4月至2023年10月在南京医科大学第一附属医院收治的42例MM患者。采用新型荧光原位杂交技术以及CD138免疫磁珠分选技术联合荧光原位杂交技术（MACS-FISH）或细胞质免疫球蛋白荧光原位杂交技术（cIg-FISH）检测MM患者，使用包括1q21/1p32、p53、免疫球蛋白重链（IgH）、IgH/成纤维细胞生长因子受体3[t(4;14)]和IgH/MAF[t(14;16)]的组合探针分析细胞遗传学检测结果。在23例MM患者中，cIg-FISH和新型荧光原位杂交技术的异常检出率分别为95.7%和100.0%（>0.05）。cIg-FISH和新型荧光原位杂交技术检测1q21+、1p32-、p53缺失和IgH异常的检出率一致，分别为52.2%、8.7%、17.4%和65.2%。对IgH异常患者进一步采用t(4;14)和t(14;16)检测，两种方法的结果相同。t(4;14)的阳性率为26.7%，而未检测到t(14;16)。在19例MM患者中，MACS-FISH和新型荧光原位杂交技术的异常检出率分别为73.7%和63.2%（>0.05）。MACS-FISH检测1q21+、1p32-和IgH异常的阳性率略高于新型荧光原位杂交技术；然而，差异无统计学意义（所有P值>0.05）。新型荧光原位杂交技术对MM患者细胞遗传学异常的检出率较高，与MACS-FISH和cIg-FISH具有良好的一致性。
